PD-1/PD-L1
Gli inibitori di PD-1/PD-L1 sono inibitori del checkpoint immunitario che bloccano l'interazione tra la proteina di morte cellulare programmata 1 (PD-1) sui linfociti T e il suo ligando PD-L1 sulle cellule tumorali. Questa interazione sopprime normalmente la risposta immunitaria e permette alle cellule tumorali di sfuggire al riconoscimento immunitario. Inibendo PD-1/PD-L1, questi inibitori potenziano la capacità del sistema immunitario di riconoscere e distruggere le cellule tumorali, inducendo apoptosi e regressione tumorale. Gli inibitori di PD-1/PD-L1 sono fondamentali nella ricerca sull'immunoterapia e nel trattamento del cancro. Presso CymitQuimica, offriamo una gamma di inibitori di PD-1/PD-L1 di alta qualità per supportare la tua ricerca in immuno-oncologia, apoptosi e terapia del cancro.
Trovati 184 prodotti per "PD-1/PD-L1".
Filtra per
Percentuale di purezza
0
100
|
0
|
50
|
90
|
95
|
100
- Prezzo più basso
- Prezzo più alto
- Purezza più bassa
- Purezza più alta
- Consegna più veloce
Penpulimab
CAS:Penpulimab is a monoclonal antibody targeting PD-1 with antitumor activity, used in studies of pancreatic cancer.Purezza:96.8% (SEC-HPLC) - 96.8% (SEC-HPLC)Colore e forma:Transparent LiquidPeso molecolare:145.14 kDa (Predicted)Sintilimab
CAS:Sintilimab (IBI308), an IgG4 monoclonal antibody, blocks PD-1, enhancing T-cell anti-tumor response; treats Hodgkin's, lung, and esophageal cancers.Purezza:> 95% - >95.0% (SDS-PAGE); 95.0% (SEC-HPLC)Colore e forma:LiquidPeso molecolare:143.78 kDa (Predicted)Zimberelimab
CAS:Zimberelimab (GLS-010) is a humanized antibody targeting PD-1, with anticancer activity.Purezza:95%Colore e forma:Transparent LiquidPeso molecolare:146.54 kDa (Predicted)AUNP-12 acetate
AUNP-12 acetate is a polypeptide inhibitor of PD-1 that is equivalent to PD-1 and PD-2 in inhibiting lymphocyte proliferation and effector fuction, in additionFormula:C144H230N40O50Purezza:95.07% - 99.29%Colore e forma:White SolidPeso molecolare:3321.61Durvalumab
CAS:Durvalumab is a humanized antibody for cancer, inhibiting PD-L1/PD-1 and CD80 interactions at very low concentrations.Purezza:97.2% (SDS-PAGE); 95.3% (SEC-HPLC) - 97.7% (SDS-PAGE); 99.59% (SEC-HPLC)Colore e forma:Transparent LiquidPeso molecolare:146.03 kDa (Predicted)BMS-1001 hydrochloride
CAS:BMS-1001 hydrochloride is an orally active inhibitor of human PD-1/PD-L1 immune checkpoint with low-toxicity in cells.BMS-1001 alleviates the inhibitory effectFormula:C35H35ClN2O7Purezza:97.36%Colore e forma:SolidPeso molecolare:631.115Budigalimab
CAS:Budigalimab (ABBV 181) is a humanized monoclonal antibody targeting PD-1 with potential antitumor activity.Purezza:97% (SDS-PAGE); 98.8% (SEC-HPLC) - 97% (SDS-PAGE); 98.8% (SEC-HPLC)Colore e forma:Transparent LiquidPeso molecolare:145.72 kDa (Predicted)Dostarlimab
CAS:Dostarlimab (TSR-042) is an immune checkpoint inhibitor targeting PD-1, blocking its interaction with its ligands PD-L1 and PD-L2.Purezza:>95%Colore e forma:Transparent LiquidPeso molecolare:144.18 kDa (Predicted)Tislelizumab
CAS:Tislelizumab, a PD-1 receptor monoclonal antibody, reduces Fcγ interaction and T cell clearance in advanced squamous NSCLC research.Purezza:95.07%Colore e forma:Transparent LiquidPeso molecolare:145 kDa (Predicted)Ezabenlimab
CAS:Ezabenlimab (BI-754091) is an anti-PD-1 mAb, Kd 6 nM, blocks PD-1/PD-Ls, boosts T-cell IFN-γ, inhibits tumors in vivo.Purezza:99.1% (SDS-PAGE); 96.9% (SEC-HPLC) - 99.1% (SDS-PAGE); 96.9% (SEC-HPLC)Colore e forma:Transparent LiquidPeso molecolare:145.21 kDa (Predicted)Spartalizumab
CAS:"Spartalizumab (PDR001), a humanized IgG4 monoclonal antibody, targets PD-1 to inhibit PD-L1/L2 interactions, useful in ATC research."Purezza:SDS-PAGE:95.2%;SEC-HPLC:96.3%Colore e forma:Transparent LiquidPeso molecolare:145.74 kDa (Predicted)Sotiburafusp alfa
CAS:Sotiburafusp alfa is a humanized bispecific fusion protein comprising a VEGFR-1 extracellular domain fragment (129-228, 1-100 in the current sequence) connectedPurezza:98%Colore e forma:SolidPD-1/PD-L1-IN-9
CAS:PD-1/PD-L1-IN-9, with an IC50 of 3.8 nM, is a potent and orally active inhibitor of the PD-1/PD-L1 interaction.Formula:C22H24N2O2Purezza:99.92%Colore e forma:SolidPeso molecolare:348.4382Eciskafusp alfa
CAS:Eciskafusp alfa, a cis-targeted IL2v immunocytokine, acts on programmed cell death 1 (PDCD1, commonly known as PD-1), preferentially targeting antigen-specificPurezza:98%Colore e forma:SolidIparomlimab
CAS:Iparomlimab serves as a functional therapeutic tool specifically designed to enable the precise detection and neutralization of the PD-1 protein which plays a pivotal role in the induction of peripheral tolerance and tumor immune evasion during strictly monitored laboratory observation periods and molecular investigations to evaluate the pharmacological potential of targeted checkpoint inhibition in specialized preclinical research environments to facilitate the study of cancer immunotherapies.Purezza:95%Colore e forma:Transparent LiquidPeso molecolare:146.70 kDa (Predicted)MS1-96
MS1-96 is an orally active PD-L1 (programmed death-ligand 1) degrader. It effectively reduces PD-L1 protein expression levels in various colorectal cancer (CRC) cell lines. The compound loses its ability to induce PD-L1 degradation upon HIP1R knockdown. MS1-96 binds directly to PD-L1 (KD= 2.58 μM) and enhances the interaction between HIP1R and PD-L1, altering PD-L1's intracellular transport in clathrin-coated vesicles. Additionally, MS1-96 induces abnormal N-glycosylation of PD-L1, leading to protein instability and accelerated lysosome-mediated degradation. MS1-96 is applicable for colorectal cancer research.PD-1/PD-L1-IN-52
PD-1/PD-L1-IN-52 (Compound Ⅲ-5) is an orally active inhibitor of PD-1/PD-L1 interaction, exhibiting an IC50 of 109.9 nM. It demonstrates antitumor activity in a C57BL/6 mouse model of MC38 colon carcinoma cells expressing human PD-1, achieving a tumor growth inhibition (TGI) rate of 49.6%.Colore e forma:Odour SolidTPP-1 TFA
TPP-1 TFA is a high-affinity PD-L1 inhibitor (KD=95nM) that boosts T-cell function to curb tumor growth.Formula:C109H151F3N34O34S2Colore e forma:SolidPeso molecolare:2602.69HLX43
HLX43 is an ADC targeting PD-L1 with DAR=8 and a cleavable linker that releases C24, possessing both immune blockade and bystander killing effects.Purezza:95% - 98.30% (SEC-HPLC)Peso molecolare:153.06 kDa (Predicted)Human PD-L1 inhibitor I
CAS:Human PD-L1 inhibitor I, a peptide, blocks PD-L1/PD-1 interaction with 3.39 μM affinity.Formula:C110H152N26O32Colore e forma:SolidPeso molecolare:2350.576
